Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biolase's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1.96 Mil. Biolase's Total Assets for the quarter that ended in Dec. 2023 was $35.10 Mil.
Therefore, Biolase's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.06.
The historical rank and industry rank for Biolase's Equity-to-Asset or its related term are showing as below:
BIOL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01 Med: 0.37 Max: 0.71
Current: 0.06
During the past 13 years, the highest Equity to Asset Ratio of Biolase was 0.71. The lowest was 0.01. And the median was 0.37.
BIOL's Equity-to-Asset is ranked worse than 92.06% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs BIOL: 0.06
Biolase Equity-to-Asset Historical Data
The historical data trend for Biolase's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biolase's Equity-to-Asset
For the Medical Devices subindustry, Biolase's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biolase's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Biolase's Equity-to-Asset falls into.
Biolase Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Biolase's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biolase (NAS:BIOL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Biolase Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Biolase's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOL has been successfully added to your 